Abstract: Oxyalkyne compounds corresponding to the formula I ##STR1## in which the substituent Y in the meta- or para-position is R.sup.1 represents CH.sub.3 or NH.sub.2, R.sup.2 represents H or CH.sub.3, R.sup.3 represents H, C.sub.1-3 -alkyl or COCH.sub.3, and Ar represents an aromatic residue selected from the group ##STR2## with the proviso that the substituents R.sup.4, R.sup.5 and R.sup.6 are the same or different and each substituent represents H, F, Cl, Br, C.sub.1-6 -alkyl, CF.sub.3 or C.sub.1-6 -alkoxy, and R.sup.7 represents H, F, Cl, Br, C.sub.1-3 -alkyl or CF.sub.3,in the form of their racemates or mixtures of diastereoisomers or in optically active form, which are suitable active ingredients in pharmaceutical compositions.

Abstract: Substituted 3,4-dihydronaphthalenes of the formula I ##STR1## wherein R.sup.1 is a methyl or an amino group, R.sup.2 represents a hydrogen atom or a methyl group, and R.sup.3 is a linear or branched chain alkyl residue having 1 to 4 carbon atoms, an allyl or a crotyl group or a cyclopentyl group are disclosed which specifically inhibit 5-lipoxygenase and are useful in pharmaceutical compositions for prophylaxis and treatment of disorders attributable to the action of leucotrienes. The dihydronaphthalenes may be prepared by reacting a compound of formula II ##STR2## with hydroxylamine or a salt thereof to form the corresponding oxime, reducing the oxime to a hydroxylamine of formula III ##STR3## and introducing a --CO--R.sup.1 group.

Abstract: Substituted phenylacetylenes of the formula ##STR1## wherein one of the groups R.sub.1 is a hydrogen atom and the other represents the group of the formula ##STR2## in which R.sub.3 is hydrogen, methyl or ethyl and R.sub.4 is a methyl or an amino group and wherein R.sub.2 represents mono- or binuclear aromatic or heterocyclic residues containing sulfur, nitrogen or oxygen as hetero atoms and optionally being substituted by 1 to 3 substituents as defined, which specifically inhibit 5-lipoxygenase and are useful in pharmaceutical compositions for prophylaxis and treatment of diseases due to the action of leukotrienes.The compounds may be prepared by reacting a compound of the formula ##STR3## wherein R.sub.2 has the same meaning as above and one of the groups R.sub.7 is a hydrogen atom and the other represents the group of the formula --COR.sub.3, with hydroxylamine to form the oxime which then is reduced to the corresponding hydroxylamine compound into which the group of the formula --COR.sub.4 is introduced.

Abstract: Disclosed are new heterocyclic compounds, medicaments containing them (for oral or parenteral administration) and processes for the preparation and use of these heterocyclic compounds and medicaments. The new compounds which particularly act as inhibitors of blood platelet aggregation and as blood pressure lowering agents correspond to the general formula ##STR1## wherein R.sup.1 is hydrogen, a cation or the residue of an alcohol, R.sup.2 represents hydrogen or methyl, A is a member of the group consisting of the radicals --CH.sub.2 --CH.sub.2 --, (trans)--CH.dbd.CH-- and --C.tbd.C--, and wherein B represents an alkyl or a cycloalkyl radical. In these compounds the phenyl radical may be arranged with respect to the double bond in the E- and/or in the Z-configuration and at the carbon atom bearing the group R.sup.2 (and others) may exist RS- or S-configuration. The compounds of formula I are prepared in a manner known per se starting from derivatives of 3.alpha.,5.alpha.-dihydroxycyclopentane-1.alpha.